Agilent Technologies struck a deal on Friday to buy Stratagene, a maker of research and development tools for life science companies, for $246.2 million. The buyout offer of $10.94 cents a share represents a 29 percent premium for shareholders. Stratagene's products are used by scientists in academia, government research and industry in molecular biology, genomics, proteomics, drug discovery and toxicology. Stratagene's portfolio includes reagents for life science research and instruments.
"We see Stratagene's technology, products and expertise as being highly complementary to Agilent's life sciences portfolio, enabling us to offer our customers more complete workflow solutions," Nick Roelofs, vice president and general manager of Agilent's life sciences solutions unit, said in a statement.
- see the release on the deal
- here's the AP's report on the buyout